In­dus­try groups, CVS pick apart FDA's pro­posed path­way for gener­ics to carve out OTC in­di­ca­tions

Phar­ma in­dus­try groups like the As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines (AAM) and PhRMA are rais­ing point­ed ques­tions about an FDA plan to cre­ate a new path­way for mar­ket­ing pre­scrip­tion drugs with an ad­di­tion­al con­di­tion for non­pre­scrip­tion use (AC­NU), which would re­quire more safe­guards than the cur­rent OTC path­way but es­sen­tial­ly carve out new OTC us­es for some gener­ic drugs.

Chief among the con­cerns were: In­sur­ance com­pa­nies drop­ping cov­er­age for the Rx ver­sion, new AC­NU patents to block com­pe­ti­tion, and in­dus­try es­sen­tial­ly gov­ern­ing the path­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER